Annual Meeting Highlights of ASCO 2018 in Pancreatic Cancer

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: July 19, 2018
Expiration Date: July 19, 2019

Expected time to complete this activity as designed: 60 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Although the mortality rate of pancreatic cancer is continuing to climb, recent advances in treatment options for the disease hold promise in improving patient outcomes. In this activity, participants will hear from leading experts in pancreatic cancer as they provide a review of key abstracts presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Participants can review summaries of clinical data, including commentary from investigators, on the significance of these studies and their impact on clinical practice. The presentations will provide an overview of investigational agents as well as first- and second-line combination therapies for patients with advanced/metastatic pancreatic cancer.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with pancreatic cancer
  • Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in pancreatic cancer

  • Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in pancreatic cancer


Preliminary Result from the “Know Your Tumor” Program – Emanuel F. Petricoin III, PhD

Novel Approaches for Locally Advanced and Metastatic Pancreatic Cancer – Vincent Picozzi, Jr., MD, MMM

The Current State of Pancreatic Cancer: One Major Healthcare System’s Approach to Standardized Care Pathways in the Community for the Treatment of Pancreatic Cancer – Federico A. Sanchez, MD

Predicting Survival for (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (MPDAC) previously treated with gemcitabine-based therapy – Andrea Wang-Gillam, MD, PhD

Combination Therapy in Metastatic Pancreatic Cancer – J. Randolph Hecht, MD

BRCA1/2 Screening and Treatment in Metastatic Pancreatic Cancer – Eileen M. O’Reilly, MD

Review of two late-breaking trials: mFOLFIRINOX vs gemcitabine in resected pancreatic cancer, and preoperative chemoradiation vs immediate surgery for resectable pancreatic cancer – Andrea Wang-Gillam, MD, PhD

Instructions for Participation and Credit

This activity is eligible for credit through July 19, 2019. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

J. Randolph Hecht, MD
Professor of Clinical Medicine
David Geffen School of Medicine at UCLA
Director, UCLA Gastrointestinal Oncology Program
Los Angeles, California

Dr. J. Randolph Hecht received his medical degree from Eastern Virginia Medical School. He completed his internal medicine residency at Northwestern, followed by fellowships in gastroenterology research at the University of Chicago and in gastroenterology and medical oncology at UCLA. Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program.

Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has led and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, and leading phase I, II, and III trials with novel immunotherapy agents.

Eileen M. O’Reilly, MD
Associate Director for Clinical Research
David M. Rubenstein Center for Pancreas Cancer
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Dr. Eileen M. O’Reilly received her medical degree at Trinity College (Dublin University) in her native Ireland. She completed her residency training in Ireland and her fellowship training at Memorial Sloan Kettering Cancer Center (MSK) in New York City. Dr. O’Reilly serves as the Associate Director for Clinical Research at the David M. Rubenstein Center for Pancreas Cancer at MSK, where she is also an Attending Physician. In addition, she is Professor of Medicine at Weill Cornell Medical College.

Nationally, Dr. O’Reilly is the Chair of the Alliance Cooperative Group Gastrointestinal Cancers Committee, and serves on the Scientific Advisory Board of the Pancreatic Cancer Action Network, NCCN Pancreas Panel, and is on the Board of the National Pancreas Foundation and ASCO IMT Committee. Her institutional responsibilities include Associate Chairpersonship of the MSK Institutional Review & Privacy Board (IRB), membership in the Research Council, Chair of the Continuing Medical Education (CME) Committee, and Chair of the Data and Safety Monitoring Committee (DSMC).

Dr. O’Reilly is the Principal Investigator of multiple phase I, II, and III trials in pancreas cancer and has authored/co-authored multiple articles, editorials, and book chapters. Her major research focus and clinical activities include pancreatic and hepatobiliary malignancies, and her research initiatives include integration of molecular and genetic-based therapies for the treatment of pancreas cancer, along with development of adjuvant and neoadjuvant therapies and identification of biomarkers that may be used to select therapy. In addition, Dr. O’Reilly teaches and mentors oncology fellows, junior faculty, residents and house-staff, and has won numerous teaching and other awards.

Emanuel F. Petricoin III, PhD
University Professor
Center for Applied Proteomics and Molecular Medicine
George Mason University
Fairfax, Virginia

Dr. Emanuel F. Petricoin received his PhD in microbiology from the University of Maryland at College Park. He is a University Professor and the Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University. The focus of CAPMM is the invention and use of proteomics technologies for personalized therapy, molecular diagnostics, and biomarker discovery. Dr. Petricoin is also the Chief Science Officer and co-founder of Perthera, Inc., a leading precision medicine company that empowers all cancer patients and oncologists globally with the most comprehensive molecular profiling and data analytics process. In addition, he is co-founder of Ceres Nanosciences, Inc., which develops tools for diagnostics and precision medicine applications; Theranostics Health, Inc.; and the Human Proteomic Organization (HUPO). Dr. Petricoin has authored/co-authored nearly 400 peer-reviewed publications and more than 45 book chapters. He is a senior editor for Cancer Epidemiology Biomarkers and Prevention and on the editorial board of JCO Precision Oncology, Proteomics, Biomedical Microdevices, Proteomics-Clinical Applications, Proteomics-Protocols, Molecular, and Carcinogenesis, Journal of Personalized Medicine. Dr. Petricoin is also a co-inventor on 40 filed and published patents.

Vincent Picozzi, Jr., MD, MMM
Pancreas Center of Excellence
Digestive Disease Institute
Virginia Mason Medical Center
Seattle, Washington

Dr. Vincent Picozzi received his medical degree from Stanford University in Stanford, California. He completed his internship and residency at Harvard University, Brigham and Women’s Hospital, and returned to Stanford University to complete his fellowships in hematology and oncology. In addition, Dr. Picozzi has completed a master of medical management (MMM) degree at Tulane University. He is currently Director of the Pancreas Center of Excellence, Digestive Disease Institute, as well as a practicing physician in the Division of Hematology-Oncology, at Virginia Mason Medical Center in Seattle, Washington.

Dr. Picozzi has board certification from National Board of Medical Examiners and from the American Board of Internal Medicine in internal medicine, hematology, and oncology. He holds professional memberships in the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), and the Pancreatic Cancer Action Network (PANCAN). He is on the Board of Directors (and a founding member) of the Washington State Medical Oncology Society, as well as the Providence Hospice of King County Foundation.

Serving patients with hematologic and oncologic disorders is Dr. Picozzi’s calling in life. His mission is to elevate the relationship between cancer patients and their providers to a premier level of importance in our society. In particular, serving patients with pancreaticobiliary cancer has been the central ministry of his professional career. His immediate goal is to assist in the transformation of perceptions and outcomes for this disorder that has the poorest prognosis of any common cancer.

Federico A. Sanchez, MD
Hematology & Oncology
Aurora Sinai Medical Center
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin

Dr. Federico Sanchez earned his medical degree from Universidad Francisco Marroquin in Guatemala, Guatemala. His internal medicine residency was completed at Albany Medical Center, Albany, NY. He also completed a fellowship in oncology and hematology through the Medical College of Wisconsin affiliated hospitals in Milwaukee. Dr. Sanchez is a practicing hematology and oncology physician at Aurora Sinai Medical Center and Aurora St. Luke's Medical Center in Milwaukee, Wisconsin.

Dr. Sanchez  is board certified in internal medicine, medical oncology, and hematology. He has a special interest in hematological/blood disorders, lymphoma, leukemia, and lung cancer. Dr. Sanchez believes that addressing the treatment of a person as a whole is vital, and supporting the patient and family is always important to help the patient achieve a successful outcome from his/her therapies.

Andrea Wang-Gillam, MD, PhD
Associate Professor
Clinical Director
GI Oncology Program
Washington University
St. Louis, Missouri

Dr. Andrea Wang-Gillam received her medical degree and PhD from the University of Arkansas College of Medicine. She completed her internship in internal medicine at the Cleveland Clinic Foundation, and her residency in internal medicine and fellowship in hematology/oncology from the University of Arkansas for Medical Sciences. She is an Associate Professor and the Clinical Director for the GI Oncology Program in the Division of Oncology at Washington University in St. Louis, Missouri.

Board certified in internal medicine and medical oncology, Dr. Wang-Gillam holds memberships in the American Society of Clinical Oncology, the American Pancreatic Cancer Association, and the American Association for Cancer Research. Her research focuses on novel therapy developments in pancreatic cancer, and she has developed several investigator-initiated studies in pancreatic cancer. She also has served as a principal investigator for multiple pancreatic cancer studies.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-18-014-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 18-014-078


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. J. Randolph Hecht has received honoraria related to formal advisory activities from Rafael Pharmaceuticals, Inc. and as a consultant from F. Hoffmann-La Roche Ltd. and Halozyme, Inc. He has received grant support related to research activities from ARMO Biosciences, Halozyme, and Merrimack Pharmaceuticals, Inc.

Dr. Eileen O’Reilly has received consultant fees from Agios; Amgen Inc.; Antengene Corporation; Aptus Pharma Pvt. Ltd.; ASLAN Pharmaceuticals; Astellas Pharma US, Inc.; AstraZeneca; Bayer AG; Boston Scientific Corporation; Bristol-Myers Squibb Company; CARsgen Therapeutics; CASI; Celgene Corporation; CytomX Therapeutics, Inc.; Daiichi Sankyo Company Limited; Debiopharm Group; Delcath Systems, Inc.; Eisai Co., Ltd.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd.; Gilead; Halozyme, Inc.; Inovio Pharmaceuticals, Inc.; Ipsen; Merck & Co., Inc.; Onxeo; PCI Biotech; Sanofi; SERVIER; Silenseed LTD; SillaJen Biotherapeutics; Sirtex; Vicus Therapeutics; and Yakult. She has received grant support related to research activities from Agios; Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb; CASI; Celgene; Exelixis; Eli Lilly and Company; Incyte Corporation; F. Hoffmann-La Roche; Genentech, Inc.; Incyte Corporation, Inc.; MabVax Therapeutics Holdings, Inc.; MedImmune, LLC; Momenta Pharmaceuticals; Novartis; and OncoMed Pharmaceuticals, Inc.

Dr. Emanuel Petricoin has received honoraria related to formal advisory activities and consultant fees from Perthera, Inc., as well as consultant fees from Avant Diagnostics, Inc. He has received grant support related to research activities and royalties or licensing fees from George Mason University. Dr. Petricoin owns significant holdings in Ceres Nanosciences, Inc.

Dr. Vincent Picozzi has received grant support related to research activities from Celgene Corporation, Eli Lilly and Company, FibroGen, Inc., Halozyme, Inc., Ipsen, OncoMed Pharmaceuticals, Inc., Taiho Pharmaceutical Co., Ltd., Takeda Oncology, and Tyme Inc.

Dr. Federico Sanchez has not provided his disclosure information as of this release date.

Dr. Andrea Wang-Gillam has received honoraria related to formal advisory activities from Ipsen and Merrimack Pharmaceuticals, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Ipsen, and Merck & Co., Inc.

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.